Evidence map›Paper›PMID 26407225›Full record

ArticlePsychosomatic medicine2015

Association of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon Treatment.

Megan M Marron, Stewart J Anderson, Jessica Garrity, Charles F Reynolds, Francis E Lotrich

Open access · greenAbstract read
In one paragraph

Article in Psychosomatic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Reply.Arthritis care & research · 2017
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Megan M MarronFrom the Department of Biostatistics (Marron, Anderson), University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; and Department of Psychiatry (Garrity, Reynolds, Lotrich), Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Stewart J Anderson
Jessica Garrity
Charles F Reynolds
Francis E Lotrich
Committee on Publication Ethics · GBUniversity of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
RESEARCH METHODS COREP30MH090333 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REYNOLDS, CHARLES F · 2011 to 2015
$8.3M
Vulnerability to major depression: The role of delta sleep in patients receivingR01MH090250 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOTRICH, FRANCIS E · 2010 to 2014
$1.6M
Transcriptome association with inflammation-related major depressionR21MH096139 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOTRICH, FRANCIS E · 2012 to 2013
$340k
NCATS NIH HHS UL1 TR000005NIMH NIH HHS P30 MH090333NIMH NIH HHS R01 MH090250NIMH NIH HHS R21 MH096139
6 · The paper itself

Abstract

objectiveSome patients with hepatitis C starting interferon-α (IFN-α) therapy experience depression, although many patients do not develop depressive symptoms. We have found that poor sleep is associated with increased depressive symptoms on average. It is unknown whether this association holds generally or is driven by a specific, distinct subgroup. This investigation first determined whether patterns of change in depressive symptoms form clinically meaningful, distinct subgroups and then tested the extent to which sleep disturbances are associated with a less favorable depression trajectory.

methodGroup-based trajectory modeling was used on 124 patients with hepatitis C who started IFN-α therapy. The Pittsburgh Sleep Quality Index (PSQI) assessed pretreatment sleep, the Beck Depression Inventory minus the sleep question assessed depression over time, and the Structured Clinical Interview for DSM-IV provided categorical diagnoses.

resultsThree distinct subgroups were found, where each subgroup shared similar patterns of depressive symptoms over time. The groups were characterized as "nondepressed," "slow increase," and "rapid increase." The nondepressed subgroup (44.4%) experienced low depressive symptoms with little change over time. In comparison, all rapid increasers (11.3%) were diagnosed as having a mood disorder by 12 weeks of treatment. The PSQI was strongly associated with group membership, where the odds of developing a rapid increase was elevated 39% for every unit-score increase in the PSQI compared with individuals who remained nondepressed (odds ratio = 1.39, 95% confidence interval = 1.07-1.80, adjusted for depression at baseline).

conclusionsOnly a distinct subpopulation of people is notably vulnerable to a developing a rapid increase in depression symptoms during IFN-α therapy. This group may be identifiable by their markedly poor sleep before IFN-α therapy.

Indexed as

AdultAntiviral AgentsDepressionFemaleHepatitis CHumansInterferon-alphaMaleMiddle AgedSleep Wake DisordersAntiviral AgentsInterferon-alpha

Identifiers

PMID26407225
PMCPMC4757461
OpenAlexW2294912033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.